Hypolipidemic Effect of Trixis angustifolia Aqueous Extract on Triton WR-1339- and High-Fat Diet-Induced Hyperlipidemic Mice

Abstract

The aim of the present study was to evaluate the hypolipidemic effect of Trixis angustifolia aqueous extract (TxAE) on Triton WR-1339- and high-fat diet-induced hyperlipidemic mice. In the Triton model, treatment with TxAE at 100 and 200 mg/kg body weight produced a significant decrease in triglycerides and very low-density lipoprotein levels and a significant increase in high-density lipoprotein (HDL). Similarly, administration of TxAE along with the high-fat diet induced a significant decrease in serum total cholesterol, low-density lipoproteins, and increase in HDL. In addition, a phytochemical study of TxAE led to the isolation of 2 previously described compounds: pebrellin and xanthomicrol. This is the first time that these compounds have been identified in a plant extract with hypolipidemic effect. The results suggest the possible therapeutic potential of TxAE as a hypolipidemic agent supporting the usage of T. angustifolia as a traditional medicine.

Dyslipidemic effect of aqueous and ethanolic extracts of raw and roasted xoconostle (Opuntia joconostle) peel

“…The hypolipidemic effects of extracts A, B and D were superior to the administration of 200 mg/kg of R. alaternus methanolic extract in a tyloxapolinduced hyperlipidemia model, which reduced the levels of TGs by 70% and TC by 60% (Tacherfiout et al, 2018). The administration of 100 mg/kg T. angustifolia lowered the concentration of TGs by 44% (Salazar-Gomez et al, 2019). On the other hand, the results of this study were similar to those reported for T. atlanticus aqueous extracts reducing TGs by 96.4% and TC by 82.8% (p<0.01) (Ramchoun et al, As in this study, tyloxapol administration did not affect c-HDL concentration, nor did treatment with an aqueous extract of Ocimum basilicum (Amrani et al, 2006).…”

“…Treatment strategies for dyslipidemia comprise pharmacological (FDA, 2015) and nonpharmacological methods, namely, medicinal plants (Bye & Linares, 2016;Alonso et al, 2017;Aumeeruddy & Mahomoodally, 2022) that contain bioactive compounds or phytochemicals shown to reduce serum lipid levels, e.g., phenolic compounds, flavonoids, and betalains (Ramchoun et al, 2012;Ma et al, 2015;Tacherfiout et al, 2018;Salazar-Gomez et al, 2019;Yahaghi et al, 2020). Xoconostle fruit (O. joconostle) is a good source of the previously mentioned bioactive compounds (Osorio-Esquivel et al 2011;Morales et al, 2012;Morales et al, 2014).…”

“…Animal models of tyloxapol-induced hyperlipidemia are used to evaluate phytochemicals with hypolipidemic activity and study cholesterol and triglyceride metabolism (Adeneye et al, 2010;Irudayaraj et al, 2010;Jo et al, 2014;Rasouli et al, 2016;Baldissera et al, 2017;Salazar-Gomez et al, 2019). Furthermore, tyloxapol augments the TC plasma concentration by promoting the hepatic synthesis of cholesterol through accelerated HMG-CoA reductase activity (Iqbal et al, 2015) and modification of lipoprotein lipases, promoting an increase in the concentrations of triglycerides (TGs) in the blood (Irudayaraj et al, 2013).…”